Objective: A sensitive mutation detection method called co-amplification at lower denaturation temperature-polymerase chain reaction (COLD-PCR) was applied to improve the detection frequencies of expressive mutations in the H-ras gene, including exons 1 and 2, in a group of Chinese patients diagnosed with bladder cancer. Materials and Methods: The expressive mutations in the H-ras gene in 86 fresh tissues of human bladder cancer were identified by COLD-PCR or conventional PCR, followed by direct sequencing. Results: A high frequency of silent mutations of 29.1% (25 of 86) in exon 1 (c.81T>C, H27H) and activating mutations of 8.1% (7 of 86) were detected by COLD-PCR, yielding a 36% improvement in mutation detection compared with conventional PCR. No significant association was shown between activating mutations and clinicopathologic parameters, but the frequencies of silent mutations in recurrent tumors were higher than those in primary tumors (p = 0.034). Conclusions: COLD-PCR is a highly sensitive, reliable, and convenient clinical assay for mutation detection. The adoption of the method is straightforward and requires no additional reagents or instruments. Silent mutations might be important genomic alterations in bladder cancer, and play a role in bladder cancer recurrence.

Keywords:
H-ras gene, COLD-PCR, Bladder cancer, Urothelial carcinoma, Mutation
1.
Totaro A, Pinto F, Brescia A, Racioppi M, Cappa E, D’Agostino D, Volpe A, Sacco E, Palermo G, Valentini A, Bassi P: Imaging in bladder cancer: present role and future perspectives. Urol Int 2010;85:373–380.
2.
Pollard C, Smith SC, Theodorescu D: Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med 2010;12:1–20.
3.
Steinberg GD, Trump DL, Cummings KB: Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. Urol Clin North Am 1992;19:735–746.
4.
Liebert, M, Seigne J: Characteristics of invasive bladder cancers: histological and molecular markers. Semin Urol Oncol 1996;14: 62–72.
5.
Ellis RW, Defeo D, Shih TY, Gonda MA, Young HA, Tsuchida N, Lowy DR, Scolnick EM: The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature 1981;292:506–511.
6.
Shinohara N, Koyanagi T: Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment? Urol Res 2002;30:273–281.
7.
Knowles MA, Williamson M: Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res 1993;53:133–139.
8.
Fujita J, Yoshida O, Yuasa Y, Rhim JS, Hatanaka M, Aaronson SA: Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours. Nature 1984;309:464–466.
9.
Fujita J, Srivastava SK, Kraus MH, Rhim JS, Tronick SR, Aaronson SA: Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors. Proc Natl Acad Sci USA 1985;82:3849–3853.
10.
Feinberg AP, Vogelstein B, Droller MJ, Baylin SB, Nelkin BD: Mutation affecting the 12th amino acid of the c-Ha-ras oncogene product occurs infrequently in human cancer. Science 1983;220:1175–1177.
11.
Przybojewska B, Jagiello A, Jalmuzna P: H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers. Cancer Genet Cytogenet 2000;121:73–77.
12.
Czerniak B, Cohen GL, Etkind P, Deitch D, Simmons H, Herz F, Koss LG: Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol 1992;23:1199–1204.
13.
Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM: Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 2008;14:579–584.
14.
Sobin LH, Wittekind C: TNM Classification of Malignant Tumors. International Union Against Cancer (UICC), No. 6. New York, Wiley-Liss, 2002.
15.
Mostofi FK, Sobin LH, Torloni H: Histological Typing of Urinary Bladder Tumors. International Histological Classification of Tumors, No. 10. Geneva, WHO, 1973.
16.
Levesque P, Ramchurren N, Saini K, Joyce A, Libertino J, Summerhayes IC: Screening of human bladder tumors and urine sediments for the presence of H-ras mutations. Int J Cancer 1993;55:785–790.
17.
Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, Doan S, Barkoh BA, Koeppen H, Medeiros LJ, Luthra R: Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 2009;22:1023–1031.
18.
Delaney D, Diss TC, Presneau N, Hing S, Berisha F, Idowu BD, O’Donnell P, Skinner JA, Tirabosco R, Flanagan AM: GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. Mod Pathol 2009;22:718–724.
19.
Li J, Wang L, Janne PA, Makrigiorgos GM: Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR. Clin Chem 2009;55:748–756.
20.
Theodorescu D, Cornil I, Fernandez BJ, Kerbel RS: Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci USA 1990;87:9047–9051.
21.
Zhang ZT, Pak J, Huang HY, Shapiro E, Sun TT, Pellicer A, Wu XR: Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001;20:1973–1980.
22.
Chamary JV, Hurst LD: The price of silent mutations. Sci Am 2009;300:46–53.
23.
Hurst LD: Molecular genetics: The sound of silence. Nature 2011;471:582–583.
24.
Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V, Mari B, Barbry P, Mosnier JF, Hébuterne X, Harel-Bellan A, Mograbi B, Darfeuille-Michaud A, Hofman P: A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn’s disease. Nat Genet 2011;43:242–245.
25.
Raponi M, Baralle FE, Pagani F: Reduced splicing efficiency induced by synonymous substitutions may generate a substrate for natural selection of new splicing isoforms: the case of CFTR exon 12. Nucleic Acids Res 2007;35:606–613.
26.
Ratajska M, Antoszewska E, Piskorz A, Brozek I, Borg A, Kusmierek H, Biernat W, Limon J: Cancer predisposing BARD1 mutations in breast-ovarian cancer families. Breast Cancer Res Treat 2012;131:89–97.
27.
Sol-Church K, Stabley DL, Nicholson L, Gonzalez IL, Gripp KW: Paternal bias in parental origin of HRAS mutations in Costello syndrome. Hum Mutat 2006;27:736–741.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.